3D imaging of SARS-CoV-2 infected hamster lungs by X-ray phase contrast tomography enables drug testing

Jakob Reichmann,Clement Sarrazin,Sebastian Schmale,Claudia Blaurock,Anne Balkema-Buschmann,Bernhard Schmitzer,Tim Salditt
DOI: https://doi.org/10.1038/s41598-024-61746-4
IF: 4.6
2024-05-30
Scientific Reports
Abstract:X-ray Phase Contrast Tomography (XPCT) based on wavefield propagation has been established as a high resolution three-dimensional (3D) imaging modality, suitable to reconstruct the intricate structure of soft tissues, and the corresponding pathological alterations. However, for biomedical research, more is needed than 3D visualisation and rendering of the cytoarchitecture in a few selected cases. First, the throughput needs to be increased to cover a statistically relevant number of samples. Second, the cytoarchitecture has to be quantified in terms of morphometric parameters, independent of visual impression. Third, dimensionality reduction and classification are required for identification of effects and interpretation of results. To address these challenges, we here design and implement a novel integrated and high throughput XPCT imaging and analysis workflow for 3D histology, pathohistology and drug testing. Our approach uses semi-automated data acquisition, reconstruction and statistical quantification. We demonstrate its capability for the example of lung pathohistology in Covid-19. Using a small animal model, different Covid-19 drug candidates are administered after infection and tested in view of restoration of the physiological cytoarchitecture, specifically the alveolar morphology. To this end, we then use morphometric parameter determination followed by a dimensionality reduction and classification based on optimal transport. This approach allows efficient discrimination between physiological and pathological lung structure, thereby providing quantitative insights into the pathological progression and partial recovery due to drug treatment. Finally, we stress that the XPCT image chain implemented here only used synchrotron radiation for validation, while the data used for analysis was recorded with laboratory CT radiation, more easily accessible for pre-clinical research.
multidisciplinary sciences
What problem does this paper attempt to address?
The main problem this paper attempts to address is the 3D imaging of hamster lungs infected with SARS-CoV-2 using X-ray phase contrast tomography (XPCT) technology, and on this basis, to develop a high-throughput, integrated image analysis workflow to support drug testing. Specifically, the study aims to: 1. **Increase sample throughput**: To efficiently handle a statistically relevant number of samples in biomedical research, it is necessary to increase the throughput of imaging and analysis. 2. **Quantify cellular structures**: Beyond visual 3D rendering, it is necessary to quantify changes in cellular structures through morphometric parameters. 3. **Dimensionality reduction and classification**: To identify effects and interpret results, dimensionality reduction and classification are required. The research team designed and implemented a new integrated high-throughput XPCT imaging and analysis workflow for 3D histology, pathological histology, and drug testing. This method utilizes semi-automated data acquisition, reconstruction, and statistical quantification techniques, demonstrating its applicability in Covid-19 lung pathology. Using a small animal model, the research team tested several different Covid-19 candidate drugs, evaluating their effectiveness in restoring physiological cellular structures (particularly alveolar morphology). The study also employed morphometric parameter determination and optimal transport-based dimensionality reduction and classification methods to effectively distinguish between physiological and pathological lung structures, thereby providing quantitative insights into pathological progression and partial recovery due to drug treatment. In summary, this study aims to enhance the understanding of lung pathological changes post-Covid-19 infection and accelerate the drug screening process through high-throughput laboratory XPCT combined with automated image processing and statistical analysis.